Late in February 2025, the University of Pittsburgh announced that its biomedical doctoral programs would cut the incoming cohort by roughly half. The reason was not a dip in applications. It was the arithmetic set in motion on February 7, when the National Institutes of Health published a three-page notice changing how much institutions could recover for the buildings, utilities, compliance, and data systems that surround every grant-funded experiment.
The notice was procedural. Its consequences were not. On February 10, the NIH planned to cap facilities and administrative costs — the indirect cost rate — at 15 percent for current and future grants. Many large research universities had individually negotiated rates above 50 percent, and some above 60 percent. Within weeks, the first signs of strain appeared not as a policy debate, but as budget spreadsheets: a training grant that no longer balanced, a lab that could not replace a departing technician, a program that decided to admit fewer students.
What a 15 Percent Cap on Facilities and Administrative Costs Actually Does
Direct costs in a grant are the costs you can point to: a postdoc's salary, reagents, animal per diems, sequencing runs. Facilities and administrative costs are the rest. They cover the negative-pressure airflow in a virology suite, the institutional review board that reviews human subjects protocols, the hazardous waste disposal that keeps a core lab legal, the cybersecurity staff who protect patient-linked data. We often talk about direct costs as the science and indirect costs as the building, but that division understates the matter. The February guidance did not trim a marginal category. It imposed a flat 15 cents of indirect reimbursement for every dollar of modified total direct costs, replacing rates that the federal government had audited and negotiated with each institution.
The arithmetic was stark. On a simplified $1 million base, a university with a 60 percent negotiated rate would have expected up to $600,000 for facilities and administration. Under the cap, that figure becomes $150,000. The $450,000 gap does not vanish. It moves to the university, a department, a dean's office, or the investigator's other grants. What goes first when the difference is a technician's salary, a freezer alarm contract, a core facility's night shift, or the colony manager who keeps a mouse line from drifting?
Modified total direct costs — the base to which the 15 percent applied — excludes equipment costing more than $5,000, patient care costs, tuition remission, and certain subaward amounts. The exclusion matters because it means the rate does not simply apply to everything a grant buys. Even so, the flat rate was a sharp break from a system of campus-specific negotiations that had taken decades to build.
Inside the First Wave of Freeze Decisions
Pittsburgh was among the most explicit early responders, and administrators there framed the decision as a matter of patient safety as much as money. Cutting a PhD cohort by half was not a closure in the padlocked-door sense. It was the quieter version: the bench stays open, but the next person never arrives, and a line of experiments stops before it starts. The document that set off those choices, Notice NOT-OD-25-068, remains the clearest source for the specific terms of the cap.
Several biomedical programs at other major research universities took similar steps, though not all made formal announcements. Some paused staff hiring. Some held graduate admissions offers until they could model two possible futures: one under 15 percent, one under their previously negotiated rates. Principal investigators began asking what a lab could maintain if a three-year grant could no longer pay for the animal facility that housed the animals named in the same grant.
The Legal Block That Arrived Within Days
The cap never took effect as scheduled. On February 10, 2025, 22 state attorneys general went to federal court in Massachusetts. Massachusetts Attorney General Andrea Campbell led the coalition, which argued that the abrupt change would cause immediate and irreparable harm to medical research and the institutions that carry it out. U.S. District Judge Angel Kelley issued a temporary restraining order later that day, blocking the policy nationwide.
The legal fight then consolidated around a longer question: whether a single rate could be imposed across a sprawling, audited system without the rule-making process Congress and federal regulations require. Universities, medical centers, and research associations filed their own challenges, and the courts kept the policy from being implemented while the cases moved forward.
Why Indirect Costs Are Not a Slush Fund
One of the most persistent misunderstandings about indirect cost reimbursement is that it is overhead fat. It is not. Facilities and administrative costs pay for animal care staff who document daily health checks, biosafety officers who inspect viral vector work, environmental health teams who ship samples under dry ice rules, and research administrators who reconcile invoices so a lab keeps its purchasing privileges. The Association of American Medical Colleges warned that the cap would weaken the shared research infrastructure on which clinical and biomedical work depends.
Those costs do not disappear when a rate drops; they shift. A university cannot stop heating an animal facility or stop running its biosafety committee. If a federal grant no longer covers its share, the money must come from tuition funds, clinical revenue, philanthropy, or state support. At public institutions, that often means leaving a position unfilled, delaying a renovation, or reducing a student service. The 15 percent cap, in other words, was never just a change to grant accounting.
What This Means for Hiring and Graduate Admissions
The uncertainty has already reached job postings and admissions committees. Postdoctoral positions and staff scientist roles, which are funded almost entirely from grant accounts, are among the first lines held open. Faculty hiring freezes have deepened the slowdown in some biomedical departments, and admissions directors have said they would rather under-enroll than over-promise funding for five or six years.
That caution is rational. A university that commits to a PhD cohort in February is making a funding promise that extends to 2030. When the indirect rate on the training grant may be 15 percent, 60 percent, or something else entirely, the safe choice is to shrink the promise. The effect is uneven: students with fewer alternatives feel it first, and early-career scientists see fewer openings exactly when they are looking for stability.
The Forward Question for Research Universities
Even with the cap blocked, the planning itself has a price. A principal investigator cannot offer a technician a start date when the grant budget may need to be reworked in three months. A core facility cannot set next year's fees when its largest federal users are unsure how much indirect recovery will arrive. Several institutions have created bridge funds or asked departments to hold back a percentage of recovered indirect costs as a buffer.
By the time Pittsburgh's programs were trimming their lists, the question was no longer only whether 15 percent would survive a federal court. It was what a generation of labs would look like after months of planning around it. The answer will arrive first in the things that do not happen: the student who accepts a smaller offer elsewhere, the postdoc who leaves the bench for industry, the technician line that stays dark, a core facility that cancels its late shift. Those are the shutdowns that never make a headline.
Photo by Morgan Housel on Unsplash